What is 180-Day Exclusivity in US? The $100 Million Prize for First Generic
By PharmaShare Regulatory Team | US FDA Generic Strategy | August 2026
1. What is 180-Day Exclusivity?
Legal Basis: Section 505(j)(5)(B)(iv) of FD&C Act – Created by Hatch-Waxman Act 1984 to encourage generic companies to challenge weak brand patents.
Definition: If you are the First-to-File (FTF) an ANDA with a Para IV certification against a listed patent, and you successfully challenge it, FDA rewards you with 180 days where no other ANDA (except the brand’s own authorized generic) can be approved.
2. Who is Eligible for 180-Day Exclusivity?
Only 2 conditions – Both MUST be met:
| Condition | Details |
|---|---|
| 1. First-to-File (FTF) | You must be the FIRST to file ANDA with Para IV for that RLD on that day. If 2 companies file same day, both share exclusivity. |
| 2. Para IV Certification | You must file Para IV stating patent is invalid / not infringed / unenforceable. Para I, II, III do NOT get exclusivity. |
Important: Exclusivity is per product, per patent. If RLD has 3 patents, you must file Para IV against at least one. But to get market, you need to clear all.
3. How 180-Day Exclusivity Works – Step by Step Timeline
Day 100: Generic A files ANDA with Para IV – Becomes First-to-File (FTF). Sends Notice Letter to Brand within 20 days.
Day 120: Brand receives notice. Has 45 days to sue.
Day 160: Brand sues Generic A → 30-Month Stay triggered – FDA cannot give final approval till 30 months or court win.
Day 600: Court decides patent invalid OR parties settle with entry date.
Day 610: FDA grants Final Approval to Generic A.
Day 610 to Day 790 (180 days): EXCLUSIVITY PERIOD – Only Generic A + Brand’s Authorized Generic can sell. No other ANDA approved.
Day 791: FDA can now approve Generic B, C, D – Price crashes by 80-90%.
4. How Much is 180-Day Worth? Real Examples
| Drug | FTF Company | 180-Day Value (Est.) |
|---|---|---|
| Lipitor (Atorvastatin) | Ranbaxy (now Sun) | ~$600 Million in 6 months |
| Plavix (Clopidogrel) | Apotex / Dr. Reddy’s | ~$400 Million |
| Nexium (Esomeprazole) | Ranbaxy | ~$250 Million |
| Revlimid (Lenalidomide) | Dr. Reddy’s, Natco | ~$800 Million+ (high value oncology) |
Why so valuable? During 180 days, you are duopoly – Brand + You. You can price at 40-60% of brand. After 180 days, 10 generics come, price falls to 5-10% of brand.
5. Shared Exclusivity vs Single Exclusivity
- Single Exclusivity: Only 1 company filed Para IV on first day → Only 1 company gets 180 days
- Shared Exclusivity: Multiple companies filed Para IV on same day (same date) → All share 180 days. FDA approves all on same day. Market splits.
6. When Does 180-Day Clock Start & End?
This is where many companies lose money.
| Event | Effect on Clock |
|---|---|
| First Commercial Marketing | Clock STARTS on day you first sell/shipping (you must notify FDA) |
| Court Decision that patent invalid/not infringed | If you didn’t market, clock starts from court decision date (you must market within 75 days) |
| 180 Calendar Days after Start | Clock ENDS – FDA can approve other ANDAs from day 181 |
7. How to LOSE Your 180-Day Exclusivity – Forfeiture
180-day is not automatic. You can FORFEIT it under 6 conditions – 21 CFR 314.107(c)(4):
- Failure to Market: You get final approval but don’t launch within 75 days of court win or 30 months stay expiry
- Failure to get Tentative Approval within 30 months (if no litigation)
- Withdrawal of ANDA or Para IV certification
- Amendment to Non-Para IV: You change Para IV to Para III
- Patent expires / delisted before you get approval and you don’t retain Para IV
- Agreement with Brand: Anti-competitive pay-for-delay – FTC can challenge and you forfeit
Biggest Mistake: Companies get final approval but delay launch for manufacturing reasons → Lose exclusivity after 75 days. Launch planning must be ready BEFORE approval.
8. Brand’s Counter Strategy: Authorized Generic (AG)
Brand can launch its own generic via subsidiary during YOUR 180 days. FDA cannot block it.
Example: Pfizer launches Authorized Generic of Lipitor during Ranbaxy’s 180 days via Watson. So market becomes 3 players: Brand + Your Generic + AG.
Still profitable, but AG cuts your value by 30-40%.
Settlement Deals: Many brands settle with FTF – “We will not launch AG if you delay entry till X date” – FTC watches these closely.
9. How to Check Who Has 180-Day Exclusivity?
- Go to Orange Book → Search product → Click “Patent and Exclusivity Information”
- Scroll to “180-day Exclusivity Decision” or check FDA’s Paragraph IV Certifications List – Updated quarterly
- FDA also publishes “First Generic Drug Approvals” list
- Check FDA’s 180-day exclusivity tracker:
fda.gov - First Generic Drug Approvals
Conclusion – Strategy for Indian Generic Companies
If you are filing ANDA from India:
- Don’t file Para IV alone: Always have IP team analyze patent strength – Is it DS, DP, or Method of Use? Can you design around?
- File on Day 1: For NCE with 5-year exclusivity, you can file Para IV after 4 years (NCE-1). File exactly on that date at 12:00 AM US time – Every hour counts.
- Prepare for Litigation: Para IV = You WILL be sued. Budget $3-5 Million for legal per product.
- Manufacturing Ready: Have exhibit batches, stability, and launch stock ready before court decision – Otherwise you forfeit.
Remember: Para III gives you safe launch but low profit. Para IV gives you lottery ticket – High risk, high reward. 1 successful Para IV can fund 10 failed ANDAs.
⚠️ Regulatory & Legal Disclaimer
This content is for educational purposes only and not legal advice. 180-day exclusivity rules are complex and governed by 21 CFR 314.107, FDA guidances, and court decisions that change frequently. Forfeiture provisions and MMA amendments apply. Always consult US regulatory counsel and patent attorney before filing Para IV. PharmaShare is not affiliated with FDA. Information as of Aug 2026. Last Updated: Aug 21, 2026.
About the Author
Mahummed Asif is a experienced pharmaceutical Quality Assurance professional and publisher of Pharmashare. He has worked with leading Pharmaceutical organizations and has developed extensive expertise in Quality Assurance, deviation management, investigations, CAPA, QMS, Product Life Cycle Management, change control, risk management, validation, product complaints, product recalls, and regulatory compliance. He is passionate about sharing practical pharmaceutical knowledge with professionals, students, and quality practitioners across the industry.
1 thought on “What is 180-Day Exclusivity”